Marie-Lucile Figueres
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marie-Lucile Figueres has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Agnès Linglart
Université Paris Saclay, Inserm, AP-HP, Service Endocrinologie et Diabète de L'enfant, Hôpital Bicêtre Paris-Saclay , 63 Rue Gabriel Péri 94270, Le Kremlin-Bicêtre
1 shared publication Amélie Ryckewaert
Néphrologie pédiatrique, C.H.U Rennes, Rennes, France
1 shared publication- Anne Grunenwald
Équipe inflammation, complément et cancer, centre de recherche des Cordeliers, Paris, France
1 shared publication Diego Cantarovich
Institut of Transplantation - Urology - Nephrology (ITUN), Hôtel Dieu. CHU de Nantes, France ; UMR INSERM 1024. Nantes, France
1 shared publication- Dominique Charue
Inserm U970, Centre de Recherche Cardiovasculaire de Paris (PARCC), Paris, France
1 shared publication - Emanuela Tolosano
Department Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, 10126 Torino, Italy
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 21 June 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (12)
Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles
In hemolytic diseases, such as sickle cell disease (SCD), intravascular hemolysis results in the release of hemoglobin, heme, and heme-loaded membrane microvesicles in the bloodstream. Intravascular hemolysis is thus associated with inflammation and organ injury. Complement system can be activated by heme in vitro. We investigated the mechanisms by which hemolysis and red blood cell (RBC) degradation products trigger complement activation in vivo. In kidney biopsies of SCD nephropathy patients and a mouse model with SCD, we detected tissue deposits of complement C3 and C5b-9. Moreover, drug-induced intravascular hemolysis or injection of heme or hemoglobin in mice triggered C3 deposition, primarily in kidneys. Renal injury markers (Kim-1, NGAL) were attenuated in C3 –/– hemolytic mice. RBC degradation products, such as heme-loaded microvesicles and heme, induced alternative and terminal complement pathway activation in sera and on endothelial surfaces, in contrast to hemoglobin. Heme triggered rapid P selectin, C3aR, and C5aR expression and downregulated CD46 on endothelial cells. Importantly , complement deposition was attenuated in vivo and in vitro by heme scavenger hemopexin. In conclusion, we demonstrate that intravascular hemolysis triggers complement activation in vivo, encouraging further studies on its role in SCD nephropathy. Conversely, heme inhibition using hemopexin may provide a novel therapeutic opportunity to limit complement activation in hemolytic diseases.
- 21 June 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (12)
Top Cited PapersOpen AccessIntravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles
In hemolytic diseases, such as sickle cell disease (SCD), intravascular hemolysis results in the release of hemoglobin, heme, and heme-loaded membrane microvesicles in the bloodstream. Intravascular hemolysis is thus associated with inflammation and organ injury. Complement system can be activated by heme in vitro. We investigated the mechanisms by which hemolysis and red blood cell (RBC) degradation products trigger complement activation in vivo. In kidney biopsies of SCD nephropathy patients and a mouse model with SCD, we detected tissue deposits of complement C3 and C5b-9. Moreover, drug-induced intravascular hemolysis or injection of heme or hemoglobin in mice triggered C3 deposition, primarily in kidneys. Renal injury markers (Kim-1, NGAL) were attenuated in C3 –/– hemolytic mice. RBC degradation products, such as heme-loaded microvesicles and heme, induced alternative and terminal complement pathway activation in sera and on endothelial surfaces, in contrast to hemoglobin. Heme triggered rapid P selectin, C3aR, and C5aR expression and downregulated CD46 on endothelial cells. Importantly , complement deposition was attenuated in vivo and in vitro by heme scavenger hemopexin. In conclusion, we demonstrate that intravascular hemolysis triggers complement activation in vivo, encouraging further studies on its role in SCD nephropathy. Conversely, heme inhibition using hemopexin may provide a novel therapeutic opportunity to limit complement activation in hemolytic diseases.
- 1 January 2015
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 65 (1) , 122-126
Kidney Function and Influence of Sunlight Exposure in Patients With Impaired 24-Hydroxylation of Vitamin D Due to CYP24A1 Mutations
- 1 January 2015
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 65 (1) , 122-126
Kidney Function and Influence of Sunlight Exposure in Patients With Impaired 24-Hydroxylation of Vitamin D Due to CYP24A1 Mutations
- 1 January 2015
- Published by Elsevier in Human Pathology
- Vol. 46 (1) , 165-168
Crystalline light chain proximal tubulopathy with chronic renal failure and silicone gel breast implants: 1 case report
- 1 January 2015
- Published by Elsevier in Human Pathology
- Vol. 46 (1) , 165-168
Crystalline light chain proximal tubulopathy with chronic renal failure and silicone gel breast implants: 1 case report
- Open Access
- 30 March 2012
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 5 (3) , 237-239
Aspergillus arthritis and organ transplantation
We report a case of a kidney and pancreas transplanted patient, hospitalized for septic hip arthritis. The whole diagnostic work-up including synovial and bone biopsies remained negative. After inefficient empirical anti-bacterial antibiotic treatment, femoral head resection was performed and tissue analysis revealed Aspergillus fumigatus hyphae. Treatment with voriconazole along with hip replacement led to complete recovery. However, drug interaction between immunosuppressive and anti-fungal drugs was complicated by cellular acute graft rejection. Aspergillus fumigatus arthritis is an uncommon and serious infection that should be evoked especially in the case of resistance to anti-microbial antibiotics and/or an atypical clinical picture.
- 30 March 2012
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 5 (3) , 237-239
Open AccessAspergillus arthritis and organ transplantation
We report a case of a kidney and pancreas transplanted patient, hospitalized for septic hip arthritis. The whole diagnostic work-up including synovial and bone biopsies remained negative. After inefficient empirical anti-bacterial antibiotic treatment, femoral head resection was performed and tissue analysis revealed Aspergillus fumigatus hyphae. Treatment with voriconazole along with hip replacement led to complete recovery. However, drug interaction between immunosuppressive and anti-fungal drugs was complicated by cellular acute graft rejection. Aspergillus fumigatus arthritis is an uncommon and serious infection that should be evoked especially in the case of resistance to anti-microbial antibiotics and/or an atypical clinical picture.